The Charcot-Marie-Tooth Association (CMTA), a registered 501c3 serving the hereditary neuropathy patient community, announced that it has formalized a preclinical testing program that employs laboratory models of Charcot-Marie-Tooth (CMT) disorders to evaluate candidate therapeutics.
The Foundation has acquired rights to a laboratory model overexpressing the Peripheral Myelin Protein-22 (PMP22) gene, for use in its program, from the Max Planck Institute for Experimental Medicine in Göttingen, Germany (http://www.em.mpg.de). An agreement to use a laboratory model overexpressing the human PMP22 gene...
In conjunction with the CMTA, Drs. Richard Lewis, Robert Baloh, Glenn Pfeffer and their team of CMT experts are hosting a “Meet and Greet” at Cedars-Sinai...
It's time to celebrate being young, so members of the CMTA have planned an evening of fun for teens between the ages of 13 and 19. Leading the event are CMTA volunteer Yohan Bouchard and Advisory Board Members
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|Page 5 of 35|
- UNDERSTANDING CMT
- RESOURCE CENTER
- ABOUT THE CMTA